Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FX Other monoclonal antibodies and antibody drug conjugates
L01FX15 Belantamab mafodotin
D11595 Belantamab mafodotin (USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Monoclonal Antibody/Antibody-Drug Conjugate
Belantamab Mafodotin
D11595 Belantamab mafodotin (USAN)
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokine receptors
Tumor necrosis factor receptors
TNFRSF17 (BCMA, CD269)
D11595 Belantamab mafodotin (USAN) <US>
Not elsewhere classified
Cellular process
Cytoskeleton
TUBB
D11595 Belantamab mafodotin (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11595
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11595
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11595